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Abstract: 
While consumers’ health cognition and behavior are likely formed 
through multiple influences, the current study focused on the effects of 
exposure to specific content elements in direct-to-consumer advertising. The 
study revealed that consumers’ exposure to the American Psychiatric 
Association’s (APA) diagnostic guideline has potential to reduce their 
perceived lifetime risk of depression and intention to consult a health 
professional to discuss the health issue. The study further revealed when an 
antidepressant ad mentioned a long list of symptoms, exposure to the 
diagnostic guideline reduced risk perception and consultation intention 
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significantly, whereas in the presence of a short list of symptoms, the APA 
guideline had minimal impact. 
Introduction 
A large body of research shows direct-to-consumer (DTC) 
prescription drug advertising has strong potential to influence 
consumers’ health cognition and behavior. For instance, Iizuka and Jin1 
reported the pharmaceutical industry’s DTC advertising expenditure 
predicted an overall increase in consumer visits to doctors’ offices. 
Similarly, Donohue and Berndt2 found the industry expenditure on DTC 
antidepressant advertising led to an increase in the number of patient 
requests for antidepressant treatment. When doctors refuse to 
prescribe the requested drugs, patients tend to be dissatisfied and 
insist on prescriptions for the drugs they saw from the 
advertisements.3 
Although the literature suggests DTC advertising has power to 
spur the expansion of a drug brand or category, research has 
predominantly focused on revealing how consumers ’ overall exposure 
to a category of DTC advertising influences their beliefs, attitudes and 
behavior regarding health issues. There is a paucity of research 
attributing such cognitive and behavioral effects to consumer exposure 
to specific content elements strategically placed in pharmaceutical ads. 
Without research accounting for how consumers process and respond 
to specific information categories in prescription drug ads, the 
literature would present limited insights for the practice of DTC 
advertising. The current study addresses this limitation by exploring 
how exposure to specific categories of information in DTC ads 
influences consumer perception of diseases. 
Considering depression is increasingly prevalent among young 
adults4 and consumer socialization begins at early life stages,5 the 
current study is designed to explore how college students ’ perception 
of clinical depression is influenced by the information DTC 
antidepressant advertisements present regarding the symptoms of 
clinical depression. More specifically, we expect college students’ 
estimation of their lifetime risk of depression and intention to consult a 
health professional to discuss the health issue will be influenced by: 
(1) the number of depression symptoms listed in the ad; (2) the type 
of depression symptoms mentioned in the ad; and (3) whether the ad 
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provides a guideline about the way consumers should use the 
symptom information to assess their health appropriately. 
Of many potentially important diseases, the current study 
focuses on depression for the reason that although antidepressants are 
one of the most heavily advertised prescription drug categories in the 
DTC market,6 depression remains largely under-diagnosed and under-
treated.7 This study will illuminate how antidepressant ads can be used 
to influence consumer perception of the future risk of depression. 
Considering high risk perception has potential to spur preventive and 
remedial health behavior,8 the findings of this study will produce 
insights into how advertising practitioners can use DTC advertising in 
an effective and socially responsible way to expand the antidepressant 
market and help reduce the under-treatment of depression. 
Theoretical Framework 
Information on the symptoms of a disease frequently appears in 
DTC advertising. Antidepressant ads, for instance, typically present the 
symptoms of clinical depression, such as sleep disorders and difficulty 
with thinking. However, the ads present such symptoms in a variety of 
ways. For example, after listing a wide range of depression symptoms, 
an ad for Zoloft states that to be considered indicative of clinical 
depression, the symptoms must interfere with one ’ s daily life and last 
each day over a two-week period. This instruction is equivalent to the 
American Psychiatric Association’s (APA)9 guideline for the accurate 
diagnosis of depression. In comparison, an ad for Effexor XR mentions 
only one symptom, ‘wanting to be alone’, without further symptom-
related information. 
Differences in the way antidepressant ads present the 
symptoms of depression are expected to influence consumer 
perception of the future risk of depression. The principle of 
representativeness heuristic10 suggests consumers will report a higher 
subjective risk of depression as they perceive their life experiences to 
be more similar to the experiences of typical depression patients. 
Information on the symptoms of depression has potential to influence 
risk estimation by altering consumers ’ mental prototype of depression 
patients,11 which in turn will affect the perceived similarity between 
their own and the typical patients ’ life experiences. The power of 
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symptom information to influence risk perception is rooted in 
consumers ’ tendency to heuristically assume the presented symptoms 
represent the population of depression symptoms.10 
The principle of representativeness heuristic leads to the 
expectation that consumer perception of the lifetime risk of depression 
will be influenced by the number of depression symptoms listed in an 
antidepressant ad and exposure to an APA-type diagnostic guideline. 
The APA9 suggests that, to be considered indicative of clinical 
depression, one’s experiences of the symptoms of depression should 
last nearly every day over a two-week period. Therefore, the guideline 
does not permit the inference that one is depressed based on 
observation of the symptoms for a day or a few days. For this reason, 
exposure to the guideline has potential to reduce the perceived 
lifetime risk of depression by decreasing the degree to which 
individuals perceive their life experiences to resemble those of typical 
depression patients. 
However, exposure to the APA guideline will have stronger 
effects on risk perception when the ad presents a long list of 
symptoms, compared to when fewer symptoms are listed. This is 
because, given the guideline that observation of symptoms for a few 
days does not indicate depression, exposure to a large amount of 
symptom information would further corroborate one’s initial judgment 
that the future risk of depression would be low.11 In contrast, the APA 
guideline would have significantly reduced impact on risk perception 
when a smaller amount of symptom information is presented. 
Therefore, we hypothesize that when the ad presents a long list 
of symptoms, exposure to the APA guideline will significantly decrease 
the perceived lifetime risk of depression. In contrast, in the presence 
of a short list of symptoms, the APA guideline will have minimal impact 
on risk perception (H1). Once formed, risk perception is a strong 
determinant of consumer engagement in preventive and remedial 
health behaviors.8,12,13 Therefore, we hypothesize that the APA 
guideline and the number of symptoms will influence consumer 
intention to consult a health professional to discuss depression in the 
same pattern as they affect risk perception (H2). 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Medical Marketing, Vol. 10, No. 2 (April 2010): pg. 123-133. DOI. This article is © Palgrave Macmillan and 
permission has been granted for this version to appear in e-Publications@Marquette. Palgrave Macmillan does not grant 
permission for this article to be further copied/distributed or hosted elsewhere without the express permission from 
Palgrave Macmillan. 
5 
 
Similar to exposure to the APA guideline, the type of depression 
symptoms presented in the ad will also interact with the number of 
symptoms to influence risk perception. Following Menon et al,11 the 
current study categorizes the symptoms of depression into: (a) 
common symptoms, defined as the symptoms that subjects experience 
relatively frequently in their lives; and (b) uncommon symptoms, 
namely the symptoms subjects experience less frequently. 
Exposure to common symptoms would lead to the judgment 
that one’s own life experiences resemble those of typical depression 
patients, and therefore has potential to raise the perceived risk of 
depression, whereas uncommon symptoms would have the opposite 
effects.11 In addition, the effects of symptom type (that is, common 
versus uncommon) will be stronger when the ad presents a long list of 
symptoms than when fewer symptoms are listed. This is because, once 
exposed to a particular type of symptoms, receiving more symptoms 
of the same category will corroborate one’s initial judgment of the 
future risk of depression.11 
Therefore, we hypothesize that when the ad presents a long list 
of symptoms, exposure to common symptoms will result in a 
significantly higher perceived lifetime risk of depression than exposure 
to uncommon symptoms. In contrast, with a short list of symptoms, 
exposure to common versus uncommon symptoms will produce a 
minimal difference in risk perception (H3). We further expect the 
number and type of symptoms to have the same interactive effects on 
consultation intention (H4). 
Method 
Design 
A 2 (number of symptoms: two versus five) × 2 (exposure to 
the APA guideline: present versus absent) × 2 (type of symptoms: 
common versus uncommon) between-subjects design was employed 
with a non-factorial control group. Because a moderate correlation was 
expected between risk perception and consultation intention, 
multivariate analysis of variance (MANOVA) was used as the main 
method of hypotheses testing. Follow-up tests of simple effects were 
conducted for exploratory purposes. 
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Subjects and Procedure 
A total of 318 undergraduates enrolled in introductory 
advertising courses at a southern state university participated in return 
for course credit. Fifteen subjects reported they had experienced 
clinical depression. Because the question to measure the perceived 
lifetime risk of depression (that is, ‘what are the chances that you will 
suffer from depression during your lifetime?’) was considered 
irrelevant to those who had already experienced depression, the 15 
subjects were deleted from further analysis. Of the remaining 303 
subjects, 66.7 percent were females, and the average age was 20.23 
(SD= 2.16). The majority were whites (74.3 percent), followed by 
Hispanics (10.6 percent), Asian Americans (7.6 percent), and African 
Americans (5.6 percent). 
Sessions were conducted in a laboratory. Subjects participated 
in groups of 5 to 25. To differentiate clinical depression from 
temporary mood swings, subjects were instructed that ‘clinical 
depression is defined in this project as a form of medical illness that 
may require doctor’s intervention for treatment’. Then subjects were 
randomly assigned to the nine experimental groups. It took 
approximately 15 min to complete the instrument. Upon completion of 
the instrument, subjects were thanked and debriefed. 
Stimulus 
A pretest was conducted to select the five common and 
uncommon symptoms of depression. A total of 29 symptoms were 
compiled from widely cited measures of depression.9,14 Subjects (N= 
45) reported on a seven-point scale (1 =never, 7 =very frequently) 
how frequently they experienced the symptoms. The five common 
symptoms selected were sleep disorders, feeling tired for no reason, 
restlessness, difficulty with thinking and inability to make decisions. 
The five uncommon symptoms were feeling hopeless about the future, 
feeling one ’ s life is empty, inability to enjoy the things one used to 
do, feeling guilty or worthless, and having acquaintances notice that 
one is restless. 
The number and type of depression symptoms and exposure to 
the APA guideline were manipulated between subjects by exposing 
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them to different versions of information about a fictitious 
antidepressant brand. Similar to Davis,15 the study was introduced as 
a copy-test for a new advertising campaign for an antidepressant 
brand recently released by an unnamed pharmaceutical company. 
Accordingly, the stimulus was disguised as the body copy of the 
advertisement. The following is the stimulus assigned to the group that 
received two common symptoms of depression with the APA guideline. 
The copy was equal across the eight treatment groups except for the 
italicized part, where manipulations occurred. 
You have trouble sleeping through the night … You get tired for 
no reason … If these last nearly every day for two weeks, they are 
symptoms of depression. Some may say it’s ‘just in your head.’ But 
depression is a serious illness with real medical causes. While the 
causes are unknown, depression is related with an imbalance of 
chemicals in the brain. Clinical studies prove that Celsta can effectively 
correct this imbalance and relieve symptoms of depression. Celsta is 
not for everyone. It is approved for adults 18 and over. People taking 
MAOIs should not take Celsta. Side effects may include dry mouth, 
dizziness, insomnia, delayed ejaculation, diarrhea, anorexia, and 
sleepiness. Celesta is a prescription drug. Talk to your doctor about 
Celsta. Get a free educational DVD about depression and Celsta by 
calling 1-800-6-Celsta, or visiting YouNeedNewLife.com . 
Measures 
Type of Symptoms (Common versus Uncommon) 
The type of symptoms was manipulated between subjects by 
assigning them to common or uncommon symptoms of depression. 
Although the number of symptoms listed in the stimulus varied 
between two and five, for the purpose of checking the manipulation, 
subjects reported their experiences with the five common or 
uncommon symptoms after completing the dependent measures. 
The manipulation was checked separately for the subjects who 
received the APA guideline (n = 137) and those without the guideline 
(n = 136). In response to the five common or uncommon symptoms, 
subjects without the APA guideline (n = 137) answered the following 
question on a seven-point scale (1 = never, 7 = very frequently): ‘In 
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your life these days, how often do you have the following feelings / 
experiences?’ Responses to the five symptoms were averaged into a 
symptom frequency index. 
For the same common or uncommon symptoms, subjects 
exposed to the APA guideline (n =136) answered the following 
question on a seven-point scale (1= not likely at all, 7 =very likely):    
‘Looking back on your life these days, how likely would it be that you 
have the following feelings / experiences nearly every day for a given 
two-week period? ’ Responses to the five symptoms were averaged 
into a symptom likelihood index. 
Perceived Lifetime Risk of Depression 
Subjects answered in percentage the following single-item 
question: ‘What are the chances that you will suffer from depression 
during your lifetime?’ The non-factorial control group rated the lifetime 
risk to be 19.17 on the average (SD =18.88). Notably, males and 
females did not significantly differ in their risk perception (Mmales = 
17.83, SD = 23.53; Mfemales = 20.06, SD = 15.74), while 
epidemiological studies indicate the actual lifetime risk is 
approximately 25 percent for women and 12 percent for men.16,17 
Intention for Consultation 
Subjects indicated on a seven-point scale (1= strongly disagree, 
7= strongly agree) their agreement with the following statement: ‘If 
the University Health Services offered free consultation about 
depression, I would intend to participate to know more about 
depression or Celsta’, similar to the single-item scale used by Raghubir 
and Menon.18  Because the non-factorial control group was not 
exposed to any antidepressant brand, the fictitious brand name was 
replaced with ‘ antidepressants ’ in the statement for the group. Males 
and females did not differ in their consultation intention (Mmales = 3.17, 
SD = 1.53; Mfemales = 3.37, SD = 1.54), a result in sync with a minimal 
gender difference in risk perception. 
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Perceived Symptom Representativeness 
A vital assumption of the principle of representative heuristic is 
that consumers assume the presented symptoms represent the 
population of depression symptoms.10 To check if this assumption is 
valid in the sample, subjects checked on a seven-point scale (1 = not 
representative at all, 7 = highly representative) how representative a 
series of experiences were of the symptoms of depression. The 
experiences were the depression symptoms used to manipulate 
symptom type. Subjects without the APA guideline (n = 136) reported 
their judgments on the five common or uncommon symptoms. 
Subjects with the APA guideline (n = 137) reported how representative 
it was to experience the five common or uncommon symptoms‘ nearly 
every day for a given two-week period’. Responses were averaged into 
a symptom representativeness index. 
Results 
Manipulation Check 
For the subjects with no exposure to the APA guideline, the 
symptom frequency index was submitted to a 2 (number of 
symptoms: two versus five) × 2 (type of symptoms: common versus 
uncommon) factorial ANOVA. As desired, the type of symptoms had a 
significant main effect on the frequency index [Mcommon = 3.37, SD = 
1.14; Muncommon = 2.27, SD = 1.10, F(1, 132) = 33.09, P < 0.001, 𝑛𝑝
2  = 
0.20], while no other significant main or interaction effect was 
observed. 
 For the subjects exposed to the APA guideline, we conducted a 2 
(number of symptoms: two versus five) × 2 (type of symptoms: 
common versus uncommon) factorial ANOVA on the symptom 
likelihood index. The results indicated that the type of symptoms had a 
significant main effect on the likelihood index [Mcommon = 2.55, SD = 
1.25; Muncommon = 1.59, SD = 0.68, F(1, 133) = 32.20, P < 0.001, 𝑛𝑝
2 = 
0.20]). As desired, no other significant main or interaction effect was 
observed, implying the manipulation was successful. 
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 Symptom Representativeness 
To test whether consumers assume the presented symptoms 
represent the population of depression symptoms regardless of 
symptom type and exposure to the APA guideline, the symptom 
representativeness index was submitted to a 2 (number of symptoms: 
two versus five) × 2 (exposure to the APA guideline: presence versus 
absent) × 2 (type of symptoms: common versus uncommon) factorial 
ANOVA. The results showed exposure to the APA guideline did not 
have a significant main effect on the representativeness index [MAPA = 
4.64, SD = 1.89; MnoAPA = 4.50, SD = 1.65, F(1, 264) = 5.82, P = 
0.45]. However, symptom type had a significant main effect [Mcommon = 
4.05, SD= 1.68; Muncommon = 5.06, SD=1.73, F(1, 264) = 24.17, P < 
0.001], violating a vital assumption of the principle of 
representativeness heuristic. This led to the expectation that H3 and 
H4 might not be supported. No other main or two-way interaction 
effects were significant. However, the three-way interaction was 
significant [F(1, 264) = 6.45, P = 0.01]. 
H1 and H2 
Hypotheses 1 and 2 were designed to examine the interactive 
effects of the number of symptoms and exposure to the APA guideline 
on subjects’ perceived lifetime risk of depression and consultation 
intention. The two hypotheses were tested by conducting a 2 (number 
of symptoms: two versus five) × 2 (exposure to the APA guideline: 
present versus absent) × 2 (type of symptoms: common versus 
uncommon) MANOVA on risk perception and consultation intention. 
The assumption of homogeneous variance-covariance matrices was 
satisfied [Box’s M= 29.18, F(21, 245417) = 1.36, P = 0.13]. 
The MANOVA results revealed the number of symptoms × 
exposure to the APA guideline interaction was significant (see Table 1), 
indicating the effects of the APA guideline on risk perception and 
consultation intention were moderated by the amount of symptom 
information. The three-way interaction was not significant, indicating 
the significance of the two-way interaction did not depend on the type 
of symptoms. 
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The MANOVA results would be invalidated if the number of 
symptoms × exposure to the APA guideline interaction had differential 
effects on risk perception and consultation intention. If the effects 
significantly differed, conducting ANOVAs for testing H1 and H2 
separately would be more appropriate than using a MANOVA for 
testing the two hypotheses simultaneously. To check this possibility, a 
four-way mixed MANOVA was designed, entering the three 
independent variables as between-subjects factors and risk perception 
and consultation intention as a within-subjects factor. For 
comparability, scores on risk perception and consultation intention 
were Z-transformed. 
As Table 2 shows, the three-way interaction of exposure to the 
APA guideline, number of symptoms and the within-subject factor was 
not significant. This ruled out the possibility that the number of 
symptoms × the APA guideline interaction might have differential 
effects on risk perception and consultation intention. Therefore, follow-
up ANOVAs were not necessary. 
Analyses of simple effects further revealed the interaction 
largely occurred in such a pattern as specified in H1 and H2. Among 
subjects who received common symptoms, when the ad listed two 
symptoms, exposure to the APA guideline did not produce a significant 
difference in risk perception [t(62.99) = 0.32, P = 0.75, Mtwo-common-
noAPA = 27.52, SD = 25.98; Mtwo-common-APA = 29.53, SD = 25.47] or 
consultation intention [t(294) = 1.57, P = 0.12, Mtwo-common-noAPA = 2.15, 
SD = 1.28; Mtwo-common-APA  = 2.72, SD = 1.75]. In contrast, when five 
symptoms were presented, the APA guideline significantly reduced risk 
perception [t(62.35 = 2.45, P = 0.02, Mfive-common-noAPA = 33.82, SD = 
25.08; Mfive-common-APA = 20.19, SD = 20.77] and consultation intention 
[t(294)=2.07, P = 0.04, Mfive-common-noAPA = 2.73, SD = 1.35; Mfive-common-
APA = 2.00, SD = 1.35]. 
A similar pattern was observed among subjects who received 
uncommon symptoms. When the ad presented two symptoms, 
exposure to the APA guideline did not significantly reduce risk 
perception [t(56.59)= 1.10, P = 0.28, Mtwo-uncommon-noAPA = 19.89, SD = 
18.47; Mtwo-uncommon-APA = 25.91, SD = 26.32] or consultation intention 
[t(294) = 1.05, P = 0.29, Mtwo-uncommon-noAPA = 2.22, SD = 1.58; Mtwo-
uncommon-APA = 1.85, SD = 1.35]. In contrast, when five symptoms were 
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presented, the APA guideline significantly reduced consultation 
intention [t(294) = 2.73, P = 0.007, Mfive-uncommon-noAPA = 3.15, SD = 
1.58; Mfive-uncommon-APA = 2.19, SD = 1.43]. The APA guideline reduced 
risk perception, but the reduction did not reach statistical significance [ 
t(64.31) =1.11, P =0.27, Mfive-uncommon-noAPA = 26.33, SD=22.47; Mfive-
uncommon-APA =20.64, SD =19.98]. 
H3 and H4 
Hypotheses 3 and 4 were designed to examine the effects of the 
number of symptoms and the type of symptoms on perceived lifetime 
risk of depression and consultation intention. Table 1 shows the 
number × type of symptoms interaction was not significant, indicating 
the effects of symptom type on the two dependent variables did not 
depend on the amount of symptom information. Therefore, H3 and H4 
were not supported. Table 1 also shows the three-way interaction was 
not significant, implying the non-significance of the number × type of 
symptoms interaction did not depend on whether subjects received the 
APA guideline or not. Further, the effects of the number × type of 
symptoms interaction were not moderated by the within-subject factor 
(see Table 2), indicating the two-way interaction had equivalent 
effects on risk perception and consultation intention. 
Analyses of simple effects also revealed the effects of symptom 
type on risk perception and consultation intention were equivalent 
whether the ad presented two or five symptoms. Among subjects with 
no exposure to the APA guideline, when the ad presented two 
symptoms, exposure to common symptoms did not produce higher 
risk perception [t(57.06) = 1.40, P = 0.17, Mtwo-common-noAPA = 27.52, SD 
= 25.98; Mtwo-uncommon-noAPA = 19.89, SD = 18.47] or stronger 
consultation intention [t(294) = 0.19, P = 0.85, Mtwo-common-noAPA  = 
2.15, SD = 1.28; Mtwo-uncommon-noAPA = 2.22, SD = 1.58] than exposure 
to uncommon symptoms. Similarly, when five symptoms were 
presented, the type of symptoms did not lead to a significant 
difference in risk perception [t(63.24) = 1.28, P = 0.21, Mfive-common-
noAPA = 33.82, SD = 25.08; Mfive-uncommon-noAPA = 26.33, SD = 22.47] or 
consultation intention [t(294) = 1.18, P = 0.24, Mfive-common-noAPA = 2.73, 
SD = 1.35; Mfive-uncommon-noAPA = 3.15, SD = 1.58]. 
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Among subjects who received the APA guideline, when the ad 
presented two symptoms, subjects exposed to common symptoms did 
not report a higher risk perception [t(63.00) = 0.56, P = 0.58, Mtwo-
common-APA = 29.53, SD = 25.47; Mtwo-uncommon-APA = 25.91, SD = 26.32], 
but reported stronger consultation intention [t(294) = 2.41, P = 0.02, 
Mtwo-common-APA = 2.72, SD = 1.75; Mtwo-uncommon-APA = 1.85, SD = 1.35] 
than those exposed to uncommon symptoms. When five symptoms 
were presented, symptom type did not lead to a significant difference 
in risk perception [t(69.90) = 0.09, P = 0.93, Mfive-common-APA = 20.19, 
SD = 20.77; Mfive-uncommon-APA = 20.64, SD= 19.98] or consultation 
intention [t(294)= 0.59, P = 0.57, Mfive-common-APA = 2.00, SD = 1.35; 
Mfive-uncommon-APA = 2.19, SD = 1.43]. 
Discussion 
While consumers ’ perceived risk of a disease and engagement 
in preventive and remedial actions are likely formed through multiple 
sources of influence, this study focused on the effects of exposure to 
specific content elements strategically placed in DTC advertising. 
Based on the framework of representative heuristic, we suggested 
college students ’ exposure to the APA diagnostic guideline has 
potential to reduce their perceived lifetime risk of depression and 
intention to consult a health professional to discuss depression. The 
findings of this study revealed when the ad mentioned a relatively long 
list of symptoms, exposure to the diagnostic guideline reduced risk 
perception and consultation intention significantly, whereas in the 
presence of a short list of symptoms, the APA guideline had minimal 
impact. 
Putsis and Dhar19 suggested brand promotions produce the 
expansion of a new product category in addition to brand switching. 
This suggests promotions are not necessarily a zero-sum game. 
Donohue and Berndt2 found DTC advertising for antidepressants 
increased the number of depression diagnosis and requests for 
antidepressant treatment, implying DTC advertising contributed to the 
expansion of the antidepressant market. The findings of this study 
have implications for how practitioners can use DTC advertising in an 
effective and socially responsible way to expand a drug category. 
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How can advertising practitioners use DTC advertising to expand 
a drug category? From a marketing perspective, one may assume that 
including a diagnostic guideline such as the APA guideline regarding 
the appropriate diagnosis of clinical depression will always be 
detrimental to the growth of a drug category, because it makes the 
health problem seem more difficult to develop. This assumption may 
present an ethical dilemma for DTC advertising practitioners, because 
from the perspective of consumer welfare, presenting a diagnostic 
guideline would enable consumers to have more accurate and 
balanced information about their health problems. 
The current study illuminates how practitioners can resolve this 
dilemma by showing that a diagnostic guideline’s capability to reduce 
consumer risk perception of a disease was significantly reduced when 
the amount of symptom-related information was small. That is, the 
guideline significantly reduced consumer risk perception of depression 
only when the ad presented a large amount of symptom-related 
information. Therefore, when practitioners present a diagnostic 
guideline to avoid the criticism that DTC ads omit valuable health 
information and therefore offer limited educational value,20 they should 
consider reducing the amount of information in the ad about the 
symptoms of the health problem. 
The findings also have implications for consumer health. If some 
content elements of DTC advertising can influence consumers ’ 
perceived risk of diseases and intention for health-related behaviors, 
would the influence contribute to consumer health? To address the 
question, we conceptualized the following three possible situations. 
Situation 1: Consumers have underrated perception of the 
risk of depression, and exposure to the content elements 
leads them to have more realistic perception. 
Situation 2: Consumers have overrated perception of the risk 
of depression, and exposure to the content elements leads 
them to have further inflated perception. 
Situation 3: Consumers’ perception may be more or less 
evenly split around the figures presented by the 
epidemiological data, and exposure to the content elements 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Medical Marketing, Vol. 10, No. 2 (April 2010): pg. 123-133. DOI. This article is © Palgrave Macmillan and 
permission has been granted for this version to appear in e-Publications@Marquette. Palgrave Macmillan does not grant 
permission for this article to be further copied/distributed or hosted elsewhere without the express permission from 
Palgrave Macmillan. 
15 
 
may drive risk perception to be either more realistic or 
overrated. 
The effects may contribute to public health in the first situation, 
whereas the second situation may indicate a negative consequence. 
Interpreting the third situation is more complex. 
Our data for women indicated the first situation, as females 
from the control group perceived their lifetime risk to be 20.06 (SD = 
15.74) while the real lifetime risk of depression for women is 25 
percent.16–17 The data indicated the second situation for men, as males 
from the control group perceived their lifetime depression risk to be 
17.83 percent (SD = 23.53) while the real lifetime risk of depression 
for men is 12 percent.16 –17 For men, therefore, exposure to 
combinations of content elements in DTC antidepressant advertising 
can drive their perceived lifetime risk of depression to be significantly 
more inflated than their actual lifetime risk. 
For this reason, some may argue DTC antidepressant 
advertising may have negative social consequences among men. 
However, depending on the health problem, we suggest the potential 
of DTC advertising to produce unrealistically high risk perception may 
result in contributing to consumer welfare. For instance, considering 
depression is a largely under-treated disease,7  the power of DTC 
antidepressant advertising to raise consumer perception of the risk of 
depression should be considered as an effective and socially beneficial 
means to detect potential depressive patients and encourage them to 
seek professional help. 
Limitations and Suggestions for Future Research 
The current study has a number of limitations. First, this study 
is based on a convenient sample of college students. Therefore, the 
results may not generalize to college-age people or the general 
consumer population. Therefore, future researchers may explore how 
the results may be replicated or vary across various segments of the 
population (for example, Asian Americans, Hispanic-Americans, versus 
white Americans), research settings (for example, laboratory 
experiment versus field experiment), and a variety of disease 
categories. Second, the experimental stimuli were entirely text-based 
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in order for the effective manipulations of the content elements. Even 
though similar approaches have been used in previous research,15,21 it 
would be meaningful to replicate the findings using more realistic 
versions of antidepressant advertisements. Another issue is whether 
the findings generalize over a longer period of time. 
The study presented the stimulus and immediately measured 
risk perception and consultation intention. As Davis and Meader21 
suggested, it will be worth exploring if the effects of exposure to the 
message elements endure over longer periods of time. Future studies 
may also address the possibility that motivation, ability and 
opportunity for information processing may change the patterns of 
interactions observed, as high-elaboration reduces consumers ’ 
dependence on heuristic information processing for judgment making. 
Therefore, consumers under a high-elaboration condition may be less 
subject to the influence of the representativeness heuristic. 
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Appendix 
Table 1: MANOVA Results for Risk Perception and Consultation Intention 
 
 
 
Table 2: Mixed MANOVA Results for Risk Perception and Help-seeking Intention 
ws is a within-subjects factor including risk perception and consultation intention. 
 
  
